Clinical Trial Update: Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating chimauranib in combination with chidamide for relapsed/refractory non-Hodgkin's lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Chiauranib (Chiauranib)
• Chidamide (chidamide)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Non-hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED